Trial Profile
A 24-Week Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions Used Twice Daily in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2020
Price :
$35
*
At a glance
- Drugs Pimecrolimus (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Therapeutic Use
- Sponsors Novartis
- 20 May 2014 New trial record
- 27 Dec 2007
- 01 Jun 2006